



## Recent Advances on the Role of Intensity-Modulated Radiotherapy in Cancer

Guest Editor:

**Dr. Taro Murai**

Nagoya City University Graduate  
School of Medical Sciences,  
Nagoya, Japan

Deadline for manuscript  
submissions:

**15 October 2024**

### Message from the Guest Editor

The emergence of intensity-modulated radiotherapy (IMRT) was one of the most revolutionary events in radiation oncology in the past 20 years. It enables the optimization of doses to tumors and the sparing of normal organs with information technology. In this IMRT era, new research fields such as hypofractionation, reirradiation, and palliative stereotactic radiotherapy have been developed. Information technology, artificial intelligence, and quality control/assurance came to be the main issues in this era.

Recently, proton therapy (PT) has emerged as the next generation following IMRT. PT has a physical characteristic known as the Bragg peak, where protons deposit most of their energy over a finite range without exit dose. Despite the edge, the optimal role of PT is not as well-defined as IMRT for now. It is partially caused by the lack of enough clinical evidence that PT is superior to IMRT. If you forecast the future, IMRT may be still the main tool for most radiation oncologists in the next decade.

In this Special Issue, we aim to elucidate the role of IMRT by reviewing the literature and reporting new findings addressing some of the unanswered questions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)